Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Rousselot

Showing results (61-70 of 195) with videos related to

Pageof 20
Sort By:
Oncotarget|June 17, 2015
Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemiaJean-Emmanuel Bibault, Martin Figeac, Nathalie Hélevaut, et al.
European Heart Journal. Cardiovascular Imaging|January 9, 2017
Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicityClément Charbonnel, Raphaele Convers-Domart, Sophie Rigaudeau, et al.
Oncotarget|July 16, 2014
MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicinJuliette Lambert, Jérôme Lambert, Olivier Nibourel, et al.
Annales De Biologie Clinique|August 16, 2024
[Acquired hemophilia A and emicizumab for the treatment of bleeding: two case report and a literature review]Amélie Launois, Isabelle Martin-Toutain, Floriane Devaux, et al.
The Lancet. Oncology|October 23, 2010
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trialFrançois-Xavier Mahon, Delphine Réa, Joëlle Guilhot, et al.
Astrobiology|March 17, 2015
Methane clathrates in the solar systemOlivier Mousis, Eric Chassefière, Nils G Holm, et al.
Pharmaceutics|June 27, 2024
Constitutional DNA Polymorphisms Associated with the Plasma Imatinib Concentration in Chronic Myeloid Leukemia PatientsHeriberto Bruzzoni-Giovanelli, Habib Zouali, Mourad Sahbatou, et al.
Oncotarget|October 15, 2013
High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patientsMarc Delord, Philippe Rousselot, Jean Michel Cayuela, et al.
Haematologica|January 26, 2023
Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemiaPatrick Harrington, Richard Dillon, Deepti Radia, et al.
Blood|October 26, 2013
Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phaseClémence Roux, Franck-Emmanuel Nicolini, Delphine Rea, et al.
Pageof 20

Showing results (61-70 of 195) with videos related to

Sort By:
Pageof 20
Oncotarget|June 17, 2015
Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemiaJean-Emmanuel Bibault, Martin Figeac, Nathalie Hélevaut, et al.
European Heart Journal. Cardiovascular Imaging|January 9, 2017
Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicityClément Charbonnel, Raphaele Convers-Domart, Sophie Rigaudeau, et al.
Oncotarget|July 16, 2014
MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicinJuliette Lambert, Jérôme Lambert, Olivier Nibourel, et al.
Annales De Biologie Clinique|August 16, 2024
[Acquired hemophilia A and emicizumab for the treatment of bleeding: two case report and a literature review]Amélie Launois, Isabelle Martin-Toutain, Floriane Devaux, et al.
The Lancet. Oncology|October 23, 2010
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trialFrançois-Xavier Mahon, Delphine Réa, Joëlle Guilhot, et al.
Astrobiology|March 17, 2015
Methane clathrates in the solar systemOlivier Mousis, Eric Chassefière, Nils G Holm, et al.
Pharmaceutics|June 27, 2024
Constitutional DNA Polymorphisms Associated with the Plasma Imatinib Concentration in Chronic Myeloid Leukemia PatientsHeriberto Bruzzoni-Giovanelli, Habib Zouali, Mourad Sahbatou, et al.
Oncotarget|October 15, 2013
High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patientsMarc Delord, Philippe Rousselot, Jean Michel Cayuela, et al.
Haematologica|January 26, 2023
Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemiaPatrick Harrington, Richard Dillon, Deepti Radia, et al.
Blood|October 26, 2013
Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phaseClémence Roux, Franck-Emmanuel Nicolini, Delphine Rea, et al.
Pageof 20